Simultaneous Spectrophotometric Estimation of Metformin, Saxagliptin and Dapagliflozin in Marketed Formulations

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and/or decreased production, resulting in elevated blood sugar levels. It is rapidly spreading around the world and has become a leading cause of mortality in recent years. The basic goal of T2DM treatment is to maintain a healthy blood sugar level. It is a difficult undertaking to develop a single analytical method for estimating individual drugs from a multidrug combination. A novel, simple, precise, accurate, repeatable, and effective UV spectrophotometric approach is developed and validated for the simultaneous quantification of a ternary combination of metformin (MET), saxagliptin (SXG), and dapagliflozin (DAG) (DGF). The FDA recently authorised bulk forms and mixed in tablet dosage forms for use in the treatment of Type 2 diabetes mellitus using the simultaneous equation approach. Methanol: water (80:20 v/v) was used to make the standard and sample solutions. MET, SXG, and DGF had maximum values of 232.0, 212.0, and 272.0nm, respectively. The calibration curves for MET, SXG, and DGF are linear in the concentration ranges of 10-50g/mL, 1-5g/mL, and 5-25g/mL, respectively. According to ICH rules, the results of the simultaneous equation technique analysis were examined and validated for various parameters.